Arrowhead Pharmaceuticals vs Kiniksa Pharmaceuticals International
ARWR and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and KNSA compare
Kiniksa Pharmaceuticals International is the larger company, worth 2.5 times as much as Arrowhead Pharmaceuticals ($14.9B against $6.1B).
Kiniksa Pharmaceuticals International grew revenue faster over the last twelve months (58.2% versus 16.8% for Arrowhead Pharmaceuticals).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −47.8% at Arrowhead Pharmaceuticals.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | KNSA |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | $14.9B |
| Share price | $42.99 | $95.11 |
| Change, 1 year | 4.2% | 136% |
| Change, 5 years | −40.3% | 716% |
| Beta (5Y) | 1.57 | 0.15 |
| Employees | 711 | 366 |
| StockData Score | ||
| Total score | 5 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 73.2× |
| P/S | 9.1× (better) | 15.8× |
| P/B | 13.0× (better) | 21.0× |
| EV/EBITDA | – | 109× |
| P/FCF | – | 75.8× |
| FCF yield | −1.2% | 1.3% (better) |
| Fair value | $31.89 | $16.72 |
| Margin of safety | −34.8% (better) | −469% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 58.2% (better) |
| Revenue growth, 5Y average | 56.6% | – |
| Net income growth (TTM) | – | 205% |
| EPS growth (TTM) | – | 189% |
| Profitability | ||
| Gross margin | – | 90.2% |
| Operating margin | −33.8% | 13.8% (better) |
| Net margin | −47.8% | 11.6% (better) |
| FCF margin | −11.2% | 20.8% (better) |
| Return on equity | −64.8% | 17.6% (better) |
| Return on invested capital | – | 60.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −2.4× | – |
| Current ratio | 5.90 (better) | 3.91 |
| Altman Z-score | 1.69 | 34.40 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 29.9% |
| Held by insiders | 4.0% | 5.1% |
| Insider net buying, 12 months | −$36.9M (better) | −$122M |
| Short interest, % of float | 8.5% | 2.9% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.